Ipinzan

Metformin Hydrochloride / Vildagliptin, the active ingredient in Ipinzan, is a Biguanide / DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control. GNH USA supplies Ipinzan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipinzan combines metformin and vildagliptin to manage hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. - Adjunct to diet and exercise: improves overall glycaemic control when lifestyle measures are insufficient. - Combination therapy: provides additional HbA1c reduction when added to other antidiabetic agents.

Ipinzan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Headache: mild to moderate intensity. - Hypoglycaemia: especially when combined with sulfonylureas or insulin. - Metallic taste: transient alteration in taste perception. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Anaphylaxis: acute allergic reaction requiring immediate medical attention. - Severe hypoglycaemia: profound low blood glucose requiring assistance.

Before prescribing Ipinzan, clinicians should consider several safety aspects.

- Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic disease: contraindicated in patients with significant liver dysfunction. - Risk of lactic acidosis: discontinue if symptoms of metabolic acidosis develop. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Drug interactions: review concomitant medications that may affect metformin or vildagliptin levels. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ipinzan can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Renal replacement therapy: metformin accumulation can lead to lactic acidosis. - Iodinated contrast agents: temporary discontinuation of metformin is recommended. - Co‑administration with other DPP‑4 inhibitors: may increase risk of adverse effects.

Moderate Interactions (Monitor Closely): - Cimetidine: may raise metformin plasma concentrations. - Beta‑blockers: can mask typical symptoms of hypoglycaemia. - Alcohol: potentiates risk of lactic acidosis, especially with impaired renal function.